Treatment of Hypoglycemia Following Gastric Bypass Surgery
Summary
Obesity is increasing worldwide and consequently the need for efficient treatment opportunities. Roux-en-Y gastric bypass (RYGB) is one of the most commonly performed bariatric procedures used in the treatment of severe obesity. The surgery results in significant and sustained weight loss and has a beneficial effect on blood glucose regulation. However, some patients experience the syndrome postprandial hyperinsulinemic hypoglycemia years after the operation, with symptoms varying from mild dizziness to confusion, loss of consciousness and seizures. Larger insulin and glucagon-like peptide 1 (GLP-1) responses to an oral glucose load are believed to play a role in the syndrome, which is not yet fully understood. There are no current treatment guidelines beside dietary recommendations. The purpose of this study is to compare different pharmacological treatments on daily blood glucose variations as well as postprandial hormonal and autonomous changes in subjects with symptoms of postprandial hyperinsulinemic hypoglycemia after RYGB.
Timeline
- Start
- 2015-10
- Primary completion
- 2017-04-08
- Completion
- 2017-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acarbose | Unknown | 50 mg | Oral |
| Subject | Liraglutide | Peptide | 1.2 mg | Subcutaneous |
| Subject | Pasireotide | Other / unclassified | 300 ug | Subcutaneous |
| Subject | Sitagliptin | Small molecule | 100 mg | Oral |
| Subject | Verapamil | Other / unclassified | 120 mg | Oral |